W. Rilling
Hepatology · 2016–2023
A researcher in the Science corpus: 2 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hepatology — 52 citations into it
- Pathology and Forensic Medicine — 7 citations into it
Whom W. Rilling trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Jordi Bruix1 , 2 (in Hepatology)
- J. Llovet (in Hepatology)
Papers from W. Rilling's perspective
Ordered by how strongly the researchers W. Rilling trusts endorse each paper. Same corpus, a different order for every researcher.
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (European Journal of Cancer)
- The International Position on Laparoscopic Liver Surgery: The Louisville Statement, 2008 (Annals of Surgery)
- Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (Hepatology)
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. (The Lancet Oncology)
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
- Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (Gastroenterology)
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
- Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
- Practical methods for incorporating summary time-to-event data into meta-analysis (Trials)